Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in ObesityApril 09, 2025 1:30 AM EDT | Source: BiophytisParis, France and Cambridge, Massachusetts--(Newsfile Corp. - April 9, 2025) -  Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, confirms the launch of the Phase 2 OBA clinical study in obesity, expected to begin as early as possible in 2025.Following the re ...